Mutant Soluble Ectodomain of Fibroblast Growth Factor Receptor-2 IIIc Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
スポンサーリンク
概要
- 論文の詳細を見る
We have developed a strong inhibitor (S252W mutant soluble ectodomain of fibroblast growth factor recptor-2 IIIc, msFGFR2) that binds FGFs strongly and blocks the activation of FGFRs. In vitro, msFGFR2 could inhibit the promoting effect of transforming growth factor (TGF)-β1 on the proliferation of primary lung fibroblasts. In vivo, msFGFR2 alleviated lung fibrosis through inhibiting the expression of α-smooth muscle actin (SMA) and collagen deposit. In Western blotting of the right lung tissues and immunohistochemical assay, we found the level of p-FGFRs, p-mitogen activated protein kinase (MAPK) and p-Smad3 in the mice of bleomycin (BLM) group treated with msFGFR2 was down dramatically compared with the mice of BLM group, which suggested the activations of FGF and TGF-β signals were blocked meanwhile. In summary, msFGFR2 attenuated BLM-induced fibrosis and is an attractive therapeutic candidate for human pulmonary fibrosis.
著者
-
Wang Ju
Institute of Bioengineering, College of Life Science and Technology, Jinan University
-
Yu Zhi-hong
Institute of Bioengineering, College of Life Science and Technology, Jinan University
-
Wang Ding-ding
Department of Biotechnology, Institute of Life Science and Biological Pharmacy, Guangdong Pharmaceutical University
-
Zhou Zhi-you
Institute of Bioengineering, College of Life Science and Technology, Jinan University
-
He Shui-lian
Institute of Bioengineering, College of Life Science and Technology, Jinan University
-
Chen An-an
Institute of Bioengineering, College of Life Science and Technology, Jinan University
関連論文
- Variation in seed germination between populations of five sub-alpine woody species from eastern Qinghai-Tibet Plateau following dry storage at low temperatures
- Mutant Soluble Ectodomain of Fibroblast Growth Factor Receptor-2 IIIc Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice